Pesquisa | Portal de Pesquisa da BVS Enfermagem

Linthicum, Mark T; Thornton Snider, Julia; Vaithianathan, Rhema; Wu, Yanyu; LaVallee, Chris; Lakdawalla, Darius N; Benner, Jennifer E; Philipson, Tomas J.

Asia Pac J Public Health ; 27(4): 407-17, 2015 May.

Artigo em Inglês | MEDLINE | ID: mdl-25301845

17.

Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments.

Eber, Michael R; Goldman, Dana P; Lakdawalla, Darius N; Philipson, Tomas J; Pritchard, Daryl; Huesch, Marco; Summers, Nicholas; Linthicum, Mark T; Sullivan, Jeff; Dubois, Robert W.

J Comp Eff Res ; 4(3): 203-213, 2015 May.

Artigo em Inglês | MEDLINE | ID: mdl-25951244

18.

Cancer mortality reductions were greatest among countries where cancer care spending rose the most, 1995-2007.

Stevens, Warren; Philipson, Tomas J; Khan, Zeba M; MacEwan, Joanna P; Linthicum, Mark T; Goldman, Dana P.

Health Aff (Millwood) ; 34(4): 562-70, 2015 Apr.

Artigo em Inglês | MEDLINE | ID: mdl-25847637

19.

The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).

Sweeney, Christopher; Nakabayashi, Mari; Regan, Meredith; Xie, Wanling; Hayes, Julia; Keating, Nancy; Li, Suhui; Philipson, Tomas; Buyse, Marc; Halabi, Susan; Kantoff, Philip; Sartor, A Oliver; Soule, Howard; Mahal, Brandon.

J Natl Cancer Inst ; 107(12): djv261, 2015 Dec.

Artigo em Inglês | MEDLINE | ID: mdl-26409187

20.

Five myths about cancer care in America.

Goldman, Dana P; Philipson, Tomas.

Health Aff (Millwood) ; 33(10): 1801-4, 2014 Oct.

Artigo em Inglês | MEDLINE | ID: mdl-25288425

Portal de Pesquisa da BVS Enfermagem

Informação e Conhecimento para a Saúde

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar:

The Value of Medical Innovation Versus Industry Rewards.

The aggregate value of cancer screenings in the United States: full potential value and value considering adherence.

Real-World Data: Policy Issues Regarding their Access and Use.

Heterogeneity in action: the role of passive personalization in comparative effectiveness research.

Real-World Data: Responses to Zito and Doshi.

Response to Epstein's comment on "heterogeneity in action".

Cost-effectiveness analysis and innovation.

Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates.

Association Between Breast Cancer Disease Progression and Workplace Productivity in the United States.

The wider public health value of HCV treatment accrued by liver transplant recipients.

Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection.

Government perspective: food labeling.

Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA.

The Quantity and Quality of Life and the Evolution of World Inequality.

Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains.

Economic burden of disease-associated malnutrition in China.

Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments.

Cancer mortality reductions were greatest among countries where cancer care spending rose the most, 1995-2007.

The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).

Five myths about cancer care in America.